Pharmacological Inhibition of EZH2 Suppresses Tumor Growth and Pulmonary Metastasis in Melanoma Cells in vitro and in vivo

To explore the anticancer mechanism of ZLD1039, RNA-seq was performed to identify global changes in gene expression in tumors treated with ZLD1039 (100 mg/kg) compared with that in vehicle-treated controls in the A375 xenograft model. The incidence and mortality rate of malignant melanoma are increasing worldwide. Metastasis limits the efficacy of current melanoma therapies and leads to poor prognosis for patients. EZH2 is an epigenetic regulator that promotes the proliferation, metastasis, and drug resistance of tumor cells by regulating transcriptional activity. EZH2 inhibitors could be effective in melanoma therapies. Herein, we aimed to investigate whether the pharmacological inhibition of EZH2 by ZLD1039, a potent and selective S-adenosyl-l-methionine-EZH2 inhibitor, suppresses tumor growth and pulmonary metastasis in melanoma cells. Results showed that ZLD1039 selectively reduced H3K27 methylation in melanoma cells by inhibiting EZH2 methyltransferase activity. Additionally, ZLD1039 exerted excellent antiproliferative effects on melanoma cells in 2D and 3D culture systems. Administration of ZLD1039 (100 mg/kg) by oral gavage caused antitumor effects in the A375 subcutaneous xenograft mouse model. RNA sequencing and GSEA analysis revealed that the ZLD1039-treated tumors exhibited changes in the gene sets enriched for “Cell Cycle” and “Oxidative Phosphorylation”, whereas the “ECM receptor interaction” gene set had a negative enrichment score. Mechanistically, ZLD1039 induced G0/G1 phase arrest by upregulating p16 and p27 and inhibiting the functions of the cyclin D1/CDK6 and cyclin E/CDK2 complex. Moreover, ZLD1039 induced apoptosis in melanoma cells via the mitochondrial reactive oxygen species apoptotic pathway, consistent with the changes in transcriptional signatures. ZLD1039 also exhibited excellent antimetastatic effects on melanoma cells in vitro and in vivo. Our data highlight that ZLD1039 may be effective against melanoma growth and pulmonary metastasis and thus could serve as a therapeutic agent for melanoma.